Vol. 17/No. 12

Outstanding individuals across all specialties of oncology were recognized at the American Society of Clinical Oncology Annual Meeting with the organization’s highest honors, the 2016 Special Awards.

Patients with nonfunctioning neuroendocrine tumors of lung or gastrointestinal origin continued to live longer when treated with the mammalian target of rapamycin inhibitor everolimus (Afinitor) than with placebo.

During the past 2 years, there have been a number of advancements in the treatment of metastatic breast cancer that include the development of novel agents and new strategies in several disease settings, resulting in improved outcomes for patients.

Although knowledge about the underlying biology of myelodysplastic syndromes has expanded rapidly in recent years, translating those findings into advances in the diagnosis and management of patients remains a significant challenge.

Next-generation sequencing technology is providing greater insight and has uncovered new and unexpected players in melanoma.

MET exon 14 skipping mutations are emerging as a particularly promising biomarker, at least in the context of lung cancer.

After years of anticipation, biosimilar versions of the most widely administered monoclonal antibodies in oncology care are moving closer to fruition for the US market, starting with a new form of trastuzumab (Herceptin).

Researchers are hoping the results of a late-stage efficacy and safety study of apalutamide in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival.

Sometimes it seems as though we’ve become addicted to a big story mentality when it comes to the American Society of Clinical Oncology Annual Meeting.

An individualized, risk-based approach to screening current and former smokers for the early detection of lung cancer would dramatically expand the population that could benefit from the preventive strategy, while saving more lives than the current US Preventive Services Task Force guidelines for lung cancer screening.